B7H3 Antibody-Drug Conjugate Linker Design for Plasma Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic molecules against B7H3, a protein overexpressed in various human malignancies, are limited in effectiveness and there is a clinical need for novel anti-B7H3 antibodies or antibody-drug conjugates.
Innovation Solution
Development of an antibody-drug conjugate specifically targeting B7H3, comprising a B7H3-targeting antibody or its antigen-binding fragment, a linker unit, and a cytotoxic drug, with specific amino acid sequences for the heavy and light chain variable regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic molecules against B7H3 are used, then treatment is provided, but effectiveness is limited
Solution Approach 1:
The patent modifies the antibody structure by changing amino acid sequences in the variable regions (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) to improve binding affinity to B7H3. The antibody-drug conjugate system changes the therapeutic parameter from conventional molecules to targeted ADC delivery, enhancing effectiveness against B7H3-expressing tumors while maintaining clinical applicability through specific antigen targeting.
2Reliability
If antibody-drug conjugate is designed with specific amino acid sequences, then affinity for human B7H3 is improved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies precise amino acid sequences for HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2), HCDR3 (SEQ ID NO: 3), LCDR1 (SEQ ID NO: 4 or 7), LCDR2 (SEQ ID NO: 5), and LCDR3 (SEQ ID NO: 6) to optimize B7H3 binding affinity. These sequence parameters are engineered through molecular biology techniques, allowing controlled production of the antibody component while maintaining high affinity through rational design rather than random screening.
3Reliability
If cytotoxic drug is conjugated to antibody, then anti-tumor effect is enhanced, but plasma stability may be compromised
Solution Approach 1:
The patent introduces a linker unit as an intermediary component between the antibody and cytotoxic drug. This linker serves as a mediator that maintains the stability of the antibody-drug conjugate in plasma by preventing premature drug release, while still enabling targeted delivery to B7H3-expressing tumor cells and subsequent cytotoxic effect upon internalization or activation at the target site.
Data Source
Figure 1~2
Figure 3~5
Figure 6~7
AI summary
The present invention provides an antibody-drug conjugate specifically binding to B7H3 and a pharmaceutical composition comprising the same. A method for using the antibody-drug conjugate of the present invention and use thereof are also provided herein.